Xtant Medical Holdings, INC 8-K filings

Xtant Medical Holdings, Inc. announced its second quarter 2026 financial results, reporting a significant decrease in revenue and a net loss, attributed to asset sales and changes in reimbursement.

Xtant Medical Holdings, Inc. reported the results of its Annual Meeting of Stockholders held on August 7, 2026, confirming the election of directors and ratification of its accounting firm.

Xtant Medical Holdings, Inc. announced its first quarter 2026 financial results, reporting a net loss of $3.1 million and raising its full-year revenue guidance to $101-$105 million.

Xtant Medical Holdings, Inc. has entered into an exclusive U.S. distribution agreement with Dilon Technologies, Inc. for the HEMOBLAST Bellows surgical hemostatic agent.

Xtant Medical reported a transformational 2025, achieving full-year profitability and positive operating cash flow, driven by revenue growth and strategic divestitures.

Xtant Medical Holdings, Inc. announced the full repayment of a $8.2 million promissory note and additional payments from Companion Spine, totaling $10.7 million, and used a portion to prepay its term loan.

Xtant Medical Holdings, Inc. announced an extension of the maturity date for an $8.2 million promissory note and a $1.742 million purchase price adjustment payment related to recent divestitures.

Xtant Medical Holdings, Inc. completed the sale of its Coflex and CoFix products and its international Paradigm Spine business for an initial $19.2 million, reducing debt and sharpening strategic focus.

Xtant Medical Holdings, Inc. reported strong third-quarter 2025 financial results, with revenue increasing 19% year-over-year and a return to positive net income and Adjusted EBITDA.

Xtant Medical Holdings, Inc. stockholders approved an amendment to its 2023 Equity Incentive Plan, increasing available shares by 12.3 million, alongside director elections and executive compensation matters at its Annual Meeting.

Xtant Medical reported strong second-quarter 2025 financial results, including an 18% revenue increase and positive net income, leading to raised full-year revenue guidance.

Xtant Medical Holdings, Inc. announced November 7, 2025, as the date for its 2025 Annual Meeting of Stockholders, establishing new deadlines for stockholder proposals and director nominations.

Xtant Medical Holdings, Inc. announced the immediate election of Abhinav Jain and Tyler Lipschultz to its Board of Directors, effective August 1, 2025, following the resignations of Robert McNamara and Lori Mitchell-Keller.

Xtant Medical Holdings, Inc. has entered into definitive agreements to sell its Coflex and CoFix spinal implant assets and all international hardware businesses to Companion Spine, LLC for a total consideration of $19.2 million, aiming to reduce debt and enhance liquidity.

Xtant Medical's first quarter of 2025 saw an 18% revenue increase, positive net income, and an improved full-year revenue guidance.

Xtant Medical reports a significant stock transaction involving OrbiMed and Nantahala Capital, alongside preliminary Q1 2025 revenue growth of 18% to 19%.

Xtant Medical Holdings announces a stock purchase agreement where OrbiMed affiliates will sell approximately 73.1 million shares to Nantahala Capital Management and other investors, alongside amendments to its credit agreements.

Xtant Medical announces a 28% increase in revenue for 2024 and projects further growth in 2025, aiming for free cash flow generation in the second half of the year.

Xtant Medical announced a 12% increase in third-quarter revenue and reaffirmed its full-year revenue guidance of $116 million to $120 million.

Xtant Medical Holdings files updated financial statements for Surgalign Holdings and pro forma information following the acquisition of Surgalign's assets.

Xtant Medical Holdings, Inc. has entered into a securities purchase agreement for a $5 million private placement with an existing institutional investor to fund working capital and general corporate purposes.

Xtant Medical announced a 48% increase in revenue for the second quarter of 2024, alongside positive adjusted EBITDA.

Xtant Medical Holdings held its 2024 annual meeting of stockholders on July 23, 2024, where all proposed directors were elected, the appointment of Grant Thornton LLP as auditor was ratified, and executive compensation was approved on an advisory basis.

Xtant Medical announced a 55% increase in first-quarter revenue and raised its full-year revenue guidance, driven by acquisitions and sales growth.

Xtant Medical announced record full-year 2023 revenue of $91.3 million, a 58% increase year-over-year, and provided 2024 revenue guidance of $112 million to $116 million.

Xtant Medical Holdings, Inc. amended its credit agreement with MidCap Financial Trust, increasing its revolving credit facility to $17 million and adding a $10 million acquisition tranche.